21 results on '"Tanwandee, T."'
Search Results
2. THU-334 - Unexpected findings from a large Asian HCV real life study
3. EE353 Cost-Effectiveness of Ravidasvir Plus Sofosbuvir Compared to the Standard of Care in Patients with Chronic Hepatitis C in the Thai Healthcare Setting.
4. FRI-148 - HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study
5. P0612 : Interferon-gamma-inducible protein 10 promoter polymorphism related with end-of-treatment HBsAg levels and had complementary role in prediction of sustained virologic response to peginterferon in HBeAg-negative chronic hepatitis B: Multicenter study
6. P.251 Long term outcome of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment
7. Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C
8. P26 Expression of MAGE-A3 and its prognostic value in hepatocellular carcinoma in Asian patients.
9. 539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
10. PP-015 Management of chronic hepatitis B (CHB) antiviral resistance - the Asia experience
11. Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand.
12. P407 HBeAg INDEX AND HBVDNA REDUCTION CAN PREDICT LONG TERM RESPONSE OF CHRONIC HEPATITIS B, HBeAg POSITIVE PATIENTS TREATED WITH PEGINTERFERON ALPHA-2a: A THREE-YEAR FOLLOW-UP.
13. 1208 BIT225, AN HCV-P7 INHIBITOR, WITH ENHANCED ANTI-HCV ACTIVITY IN COMBINATION WITH PEGYLATED INTERFERONalfa- 2b AND RIBAVIRIN IN HCV GENOTYPE-1 TREATMENT NAÏVE SUBJECTS: PHARMACOKINETIC AND RESISTANCE STUDIES.
14. 424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY
15. 69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS
16. 1142 INCREASED BONE MINERAL DENSITY IN CHRONIC HEPATITIS C PATIENTS AFTER TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN COMBINATION
17. 738 HIGHEST RATES OF RESPONSE AT WEEK 72 OF THE NEPTUNE STUDY ARE ACHIEVED WITH PEGINTERFERON ALFA-2A 180 μG FOR 48 WEEKS
18. 1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION
19. 180 ORAL L-ORNITHINE-L-ASPARTATE (LOLA) FOR PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY TREATED WITH LACTULOSE; A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL
20. 7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE
21. 502 Efficacy and safety of peginterferon alpha-2a (40KD) (PEGASYS) in patients with chronic hepatitis B who had received prior treatment with nucleos(T)IDE analogues - the pegalam cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.